According to the second quarter 2016 earnings report from Allergan, the company reports $3.7 billion in net revenues, a 2% increase from the second quarter in 2015.
In addition, the company reports $3.7 billion in branded net revenues, a 1% increase from the second quarter in 2015.
GAAP operating loss from continuing operations in the second quarter 2016 was $488 million. Non-GAAP operating income from continuing operations in the second quarter 2016 was $1.86 billion. For the second quarter 2016, adjusted EBITDA from continuing operations was $1.94 billion, compared to $2.08 billion for the second quarter 2015. The decrease was primarily due to the loss of exclusivity on NAMENDA® IR. Cash flow from operations for the second quarter of 2016 was $1.4 billion, according to a media release from Allergan.
“Allergan delivered another quarter of strong operating performance, while taking important steps to advance our evolution as a focused Growth Pharma leader,” said Brent Saunders, CEO and president, Allergan, in the release. “Our teams delivered strong revenues powered by robust performance from key brands, including BOTOX, RESTASIS, LINZESS, JUVEDERM, and LO LOESTRIN.”
“Thank you to our more than 16,000 colleagues around the world, who have delivered strong results despite a period of significant change, advanced important innovation for patients, and are the driving force behind our therapeutic area leadership and strong connection to the customers we serve,” he adds.
For more information, visit Allergan.
[Source(s): Allergan, PR Newswire]
